Browsed by
Tag: healthrelated

Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study ?>

Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study

Oral OTEZLA(R) (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis. Apremilast treatment resulted in improved health-related quality of life during 16 weeks of therapy in ESTEEM 2. Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study Patients in ESTEEM 1 trial with nail and scalp psoriasis showed significant improvement with apremilast at 16 weeks; improvements…

Read More Read More

Significantly improved health-related quality-of-life parameters were seen in patients with plaque psoriasis treated with apremilast for 16 weeks ?>

Significantly improved health-related quality-of-life parameters were seen in patients with plaque psoriasis treated with apremilast for 16 weeks

Significantly improved health-related quality-of-life parameters were seen in patients with plaque psoriasis treated with apremilast for 16 weeks; Significantly improved health-related quality-of-life parameters were seen in patients with plaque psoriasis treated with apremilast for 16 weeks; improvements were maintained through 32 weeks. Greater improvement was also seen in other efficacy and quality of life measures, including PASI-90, Physician’s Global Assessment (PGA), and Daily Life Quality Index (DLQI) for all doses. Global Health. Oral ponesimod in patients with chronic plaque psoriasis:…

Read More Read More

Psoriasis decreases the health-related quality of life (HRQOL) of the patients and their family as well (5) ?>

Psoriasis decreases the health-related quality of life (HRQOL) of the patients and their family as well (5)

Psoriasis decreases the health-related quality of life (HRQOL) of the patients and their family as well (5). It is important to consider patients’ quality of life (QOL) and its improvement in addition to their medical treatment and that is why the measurement of QOL of people with chronic diseases such as psoriasis has attracted much attention. Patients with active or inactive psoriasis completed the PSO-LIFE together with other Dermatology Quality of Life Index (DLQI) and Psoriasis Disability Index (PDI). This…

Read More Read More